The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Skin Disease in Methamphetamine Abuse

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05971043
Recruitment Status : Not yet recruiting
First Posted : August 2, 2023
Last Update Posted : August 2, 2023
Sponsor:
Information provided by (Responsible Party):
Asmaa mohamed hafez, Assiut University

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
1. To detect the skin diseases in patients using methamphetamine

Condition or disease
Methamphetamine Abuse

Detailed Description:

Methamphetamine is a stimulant drug that associated with a broad spectrum of health conditions, include addiction, mental health disorders, and overdose. The Drug Enforcement Agency (DEA) classifies it as a Schedule II drug. This means that the drug has a high potential for misuse. The drug is also called crystal meth, ice, and blue.

Methamphetamine use has increased in Egypt especially in upper Egypt. Literature on cutaneous manifestations among methamphetamine users is limited, although cellulitis, delusion of parasitosis (DOP), hyperhidrosis, formication and prurigo nodularis (PN) have been attributed to methamphetamine users. While the relationship between skin lesions and substance use in not fully defined, there is some evidence that points to the development of these itchy, red lesion also known as meth sore after meth use. Meth sores often look like small round red patches on your skin, they can often be confused with acne when they appear on the face or a rash when they appear on other parts of the body.

Meth sores form as a result of heavy meth misuse. other signs of meth abuse at the stage where sores likely to develop include:

  • Weight loss
  • Paranoia
  • Hallucinations
  • Aggressive behavior
  • Being easily distracted
  • Tooth and gum decay
  • Changes in brain structure
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Skin Disorders in Patients Using Methamphetamine
Estimated Study Start Date : August 3, 2023
Estimated Primary Completion Date : August 20, 2024
Estimated Study Completion Date : September 20, 2024

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. skin disorders in patients using methamphetamine [ Time Frame: baseline ]
    questionnaire-based study To detect the skin diseases and manifestation appears in patients using methamphetamine


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   14 Years to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
cross-sectional, questionnaire-based, study including clinical assessment of diseases severity.
Criteria

Inclusion Criteria:

  • Patients using methamphetamine

Exclusion Criteria:

  • 1. Pregnant and lactating patients. 2. Patients with chronic diseases
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05971043


Contacts
Layout table for location contacts
Contact: asmaa mohamed, master +201097507017 amelnakeeb@gmail.com
Contact: sahar ismail, professor 01008899446 saharsotohy@yahoo.com

Sponsors and Collaborators
Assiut University
Investigators
Layout table for investigator information
Study Director: Ahmed Shawkey gomaa, Lecturer Assiut University
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Asmaa mohamed hafez, principal investigator Dr asmaa mohamed hafez, Assiut University
ClinicalTrials.gov Identifier: NCT05971043    
Other Study ID Numbers: meth addiction
First Posted: August 2, 2023    Key Record Dates
Last Update Posted: August 2, 2023
Last Verified: July 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No